Silenor Approval History

Silenor (doxepin) is a low-dose oral tablet formulation of the H1 receptor antagonist doxepin indicated for the treatment of insomnia characterized by difficulties with sleep maintenance.

FDA Approval History for Silenor

DateArticle
Mar 18, 2010Approval Somaxon Announces FDA Approval of Silenor (doxepin) for the Treatment of Insomnia
Jan 25, 2010Somaxon Provides Update on New Drug Application for Silenor for the Treatment of Insomnia
Dec 18, 2009Somaxon Scheduled to Meet with FDA to Discuss Complete Response Letter for Silenor NDA
Dec  7, 2009Somaxon Receives Complete Response Letter from the FDA for Silenor NDA
Jul  7, 2009Somaxon Announces $6 Million Private Equity Financing and Acceptance of NDA Resubmission of Silenor for the Treatment of Insomnia
Jun  5, 2009Somaxon Resubmits New Drug Application for Silenor (Doxepin) for the Treatment of Insomnia
Apr  7, 2009Somaxon Provides Update on New Drug Application for Silenor (doxepin) for the Treatment of Insomnia
Feb 27, 2009Somaxon Receives Complete Response Letter from the FDA for Silenor (doxepin)
Nov 24, 2008FDA Extends Review of Somaxon Pharmaceuticals' New Drug Application for Silenor (Doxepin) by up to Three Months
Apr 15, 2008Somaxon Pharmaceuticals Announces Acceptance for Filing of New Drug Application for Silenor for the Treatment of Insomnia
Jan 31, 2008Somaxon Pharmaceuticals Submits New Drug Application for Silenor for the Treatment of Insomnia
May  9, 2007Somaxon Pharmaceuticals Provides Update on Silenor Development Program
Nov 20, 2006Somaxon Pharmaceuticals’ Silenor Demonstrates Positive Results in its Third Phase 3 Clinical Trial in Insomnia

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide
(web4)